Morgan Stanley lowered the firm’s price target on Docebo (DCBO) to $43 from $61 and keeps an Overweight rating on the shares. Despite progress selling upmarket and continued platform/product innovation, the company’s results and guidance came up short, reflecting continued deceleration in 2025, the analyst tells investors in a research note. The firm added that valuation remains attractive on lower, reset numbers, as 3.5x sales is too cheap for profitable growth software-as-a-service.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCBO:
- Docebo’s Long-Term Growth Potential: A Buy Rating Amid Strategic Shifts and AI Investments
- Docebo Reports Strong Q4 and Fiscal Year 2024 Results, Driven by New Product Launches
- Docebo reports Q4 adjusted EPS 29c, consensus 26c
- Docebo sees Q1 revenue $57M-$57.2M, consensus $58.55M
- Docebo sees FY25 revenue growth 11%-12%, consensus $246.54M